Intratumoral heterogeneity of HER-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray

被引：40

作者：

Shin, Sandra J. ^{[1
]}

Hyjek, Elizabeth ^{[1
]}

Early, Erin ^{[1
]}

Knowles, Daniel M. ^{[1
]}

机构：

[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA

来源：

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY | 2006年 / 14卷 / 04期

关键词：

HER-2/neu; gene amplification; intratumoral heterogeneity;

D O I：

10.1177/1066896906293055

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Fluorescence in-situ hybridization is increasingly being used to determine HER-2/neu status in patients with breast carcinoma. The possibility that intratumoral heterogeneity of HER-2/neu gene amplification may potentially contribute to inaccurate assessment of HER-2/neu status was investigated in routine cases of invasive mammary carcinomas. From 169 representative formalin-fixed, paraffin-embedded blocks of invasive duct mammary carcinomas with grade 3 architecture, 48 cases were analyzed by fluorescence in-situ hybridization and 59 analyses were performed. Intratumoral heterogeneity for HEB-2/neu gene amplification was demonstrated in only 5 (16%) of 31 cases where morphologically similar areas of a single tumor were analyzed. We conclude from this study that intratumoral heterogeneity of HER-2/neu gene amplification is a demonstrable but relatively uncommon occurrence. For invasive mammary carcinomas, the accurate assessment of HER-2/neu status by fluorescence in-situ hybridization analysis is not significantly confounded by intratumoral heterogeneity of HER-2/neu gene amplification in individual tumors.

引用

页码：279 / 284

页数：6

共 39 条

[11]

Fujii H, 1996, CANCER RES, V56, P1493

[12] Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites [J].

Gancberg, D ;

Di Leo, A ;

Cardoso, F ;

Rouas, G ;

Pedrocchi, M ;

Paesmans, M ;

Verhest, A ;

Bernard-Marty, C ;

Piccart, MJ ;

Larsimont, D .

ANNALS OF ONCOLOGY, 2002, 13 (07) :1036-1043

[13] Marked intratumoral heterogeneity of c-myc and CyclinD1 but not of c-erbB2 amplification in breast cancer [J].

Glöckner, S ;

Buurman, H ;

Kleeberger, W ;

Lehmann, U ;

Kreipe, H .

LABORATORY INVESTIGATION, 2002, 82 (10) :1419-1426

[14] ERBB2 AMPLIFICATION IN BREAST-CANCER ANALYZED BY FLUORESCENCE INSITU HYBRIDIZATION [J].

KALLIONIEMI, OP ;

KALLIONIEMI, A ;

KURISU, W ;

THOR, A ;

CHEN, LC ;

SMITH, HS ;

WALDMAN, FM ;

PINKEL, D ;

GRAY, JW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5321-5325

[15] Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].

Kononen, J ;

Bubendorf, L ;

Kallioniemi, A ;

Bärlund, M ;

Schraml, P ;

Leighton, S ;

Torhorst, J ;

Mihatsch, MJ ;

Sauter, G ;

Kallioniemi, OP .

NATURE MEDICINE, 1998, 4 (07) :844-847

[16]

Kuukasjarvi T, 1997, CANCER RES, V57, P1597

[17] ELEVATED SERUM C-ERBB-2 ANTIGEN LEVELS AND DECREASED RESPONSE TO HORMONE-THERAPY OF BREAST-CANCER [J].

LEITZEL, K ;

TERAMOTO, Y ;

KONRAD, K ;

CHINCHILLI, VM ;

VOLAS, G ;

GROSSBERG, H ;

HARVEY, H ;

DEMERS, L ;

LIPTON, A .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1129-1135

[18] Genetic instabilities in human cancers [J].

Lengauer, C ;

Kinzler, KW ;

Vogelstein, B .

NATURE, 1998, 396 (6712) :643-649

[19] Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining [J].

Lewis, JT ;

Ketterling, RP ;

Halling, KC ;

Reynolds, C ;

Jenkins, RB ;

Visscher, DW .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (02) :273-281

[20]

LIU E, 1992, ONCOGENE, V7, P1027

← 1 2 3 4 →